Vivotif Market Report 2026

Vivotif Market Overview

• The Vivotif market growth in the historic period has been driven by increasing incidence of typhoid in endemic regions, expansion of international travelhigh-risk areas • Market expansion is supported by increasing investments in preventive healthcare, rising travel vaccination demand • Growth Driver: Rising Typhoid Fever Incidence Fuels Growth In The Market • Asia-Pacific was the largest region in 2025.

What Is Covered Under Vivotif Market?

Vivotif is an oral vaccine for preventing typhoid fever, a potentially life-threatening illness caused by the bacterium Salmonella typhi. It is approved for use in adults and children over 6 years of age. It is advised for those at higher risk, such as travelers to endemic areas, individuals with intimate exposure to S. typhi carriers, and microbiology laboratorians working frequently with S. typhi. The main clinical indication for vivotif are typhoid, other indications. Typhoid is a bacterial infection caused primarily by Salmonella Typhi, which is transmitted through contaminated food or water. These are distributed through various distribution channels such as direct sales, online pharmacies, and retail pharmacies and are used by various end-users such as adults, and pediatric.

What Is The Vivotif Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in preventive healthcare, rising travel vaccination demand, expansion of pediatric immunization coverage, growing focus on antimicrobial resistance prevention, improved access to vaccines in emerging markets. Major trends in the forecast period include increasing adoption of oral vaccination programs, rising demand for travel-related vaccines, growing focus on preventive infectious disease management, expansion of cold-chain optimized vaccine distribution, enhanced awareness of typhoid prevention.

Global Vivotif Market Segmentation

1) By Clinical Indication: Typhoid, Other Indications 2) By Distribution Channel: Direct Sales, Online Pharmacies, Retail Pharmacies 3) By End-User: Adults, Pediatric

What Are The Drivers Of The Vivotif Market?

The increasing incidence of typhoid fever is expected to propel the growth of the vivotif market going forward. Typhoid fever is a bacterial infection caused by Salmonella Typhi, which spreads through contaminated food or water and causes fever, abdominal pain, and fatigue. The increasing incidence of typhoid fever is due to poor sanitation, lack of access to clean water, and growing antibiotic resistance, particularly in low-income regions. Vivotif helps reduce typhoid fever incidence by providing a preventive oral vaccine against Salmonella Typhi, especially in regions with poor sanitation. For instance, in August 2024, according to reports published by GOV.UK, a UK-based government platform, in 2023, around 645 cases of typhoid fever were reported in England, Wales, and Northern Ireland, marking an increase from 470 cases in 2022, indicating a rise in the incidence of the disease year-over-year. Therefore, the increasing incidence of typhoid fever is driving the growth of the vivotif industry. The rise in healthcare spending is expected to propel the growth of the vivotif market going forward. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, to maintain or improve the health and well-being of individuals and populations. Healthcare spending is attributed to an aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports vivotif by allocating funds for the research, production, and distribution of the oral typhoid vaccine, ensuring its availability and accessibility to populations at risk of typhoid fever, thereby contributing to public health efforts and disease prevention in areas with high incidence rates. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is driving the growth of the vivotif industry.

Key Players In The Global Vivotif Market

Major companies operating in the vivotif market are Bavarian Nordic A/S

What Are Latest Mergers And Acquisitions In The Vivotif Market?

In May 2023, Bavarian Nordic A/S, a Denmark-based pharmaceutical company, acquired Emergent BioSolutions for $0.274 billion. Through this acquisition, Bavarian Nordic strengthens its position in the vaccine market by adding Vivotif (for typhoid fever), Vaxchora (for cholera), and a Phase 3 Chikungunya vaccine. Emergent BioSolutions is a US-based life sciences company that develops vivotif.

Regional Insights

Asia-Pacific was the largest region in the vivotif market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vivotif Market?

The vivotif market consists of sales of oral typhoid vaccines and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vivotif Market Report 2026?

The vivotif market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vivotif industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.